Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)
A study of radiolabelled IPN60170 (Mesdopetam) elimination pathways in healthy adult male participants